医学
内科学
中止
慢性淋巴细胞白血病
不利影响
胃肠病学
置信区间
白血病
作者
John C. Byrd,Jennifer A. Woyach,Richard R. Furman,Peter Martin,Susan O’Brien,Jennifer R. Brown,Deborah M. Stephens,Jacqueline C. Barrientos,Stephen Devereux,Peter Hillmen,John M. Pagel,Ahmed Hamdy,Raquel Izumi,Priti Patel,Minhui Wang,Nitin Jain,William G. Wierda
出处
期刊:Blood
[American Society of Hematology]
日期:2021-06-17
卷期号:137 (24): 3327-3338
被引量:43
标识
DOI:10.1182/blood.2020009617
摘要
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy and safety of acalabrutinib monotherapy were evaluated in a treatment-naive CLL cohort of a single-arm phase 1/2 trial (ACE-CL-001). Adults were eligible for enrollment if chemotherapy was declined or deemed inappropriate due to comorbidities (N = 99). Patients had a median age of 64 years and 47% had Rai stage III/IV disease. Acalabrutinib was administered orally 200 mg once daily, or 100 mg twice daily until progression or intolerance. A total of 99 patients were treated; 57 (62%) had unmutated immunoglobulin heavy-chain variable gene, and 12 (18%) had TP53 aberrations. After median follow-up of 53 months, 85 patients remain on treatment; 14 discontinued treatment, mostly because of adverse events (AEs) (n = 6) or disease progression (n = 3). Overall response rate was 97% (90% partial response; 7% complete response), with similar outcomes among all prognostic subgroups. Because of improved trough BTK occupancy with twice-daily dosing, all patients were transitioned to 100 mg twice daily. Median duration of response (DOR) was not reached; 48-month DOR rate was 97% (95% confidence interval, 90-99). Serious AEs were reported in 38 patients (38%). AEs required discontinuation in 6 patients (6%) because of second primary cancers (n = 4) and infection (n = 2). Grade ≥3 events of special interest included infection (15%), hypertension (11%), bleeding events (3%), and atrial fibrillation (2%). Durable efficacy and long-term safety of acalabrutinib in this trial support its use in clinical management of symptomatic, untreated patients with CLL.
科研通智能强力驱动
Strongly Powered by AbleSci AI